Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in Thailand: A Simulation Study
Kanlaya Teerawattananon (Ophthalmology Unit, Chiangkhum Hospital, Phayao, Thailand) Saniorn Iewsakul (Ophthalmology Unit, Chiangkhum Hospital, Phayao, Thailand) Chawewan Yenjitr (International Health Policy Program, Ministry of Public Health, Nonthaburi, Thailand) Somsanguan Ausayakhun (Ophthalmology Department, Chiangmai University, Chiangmai, Thailand) Watanee Yenjitr (Ophthalmology Unit, Priest Hospital, Bangkok, Thailand) Miranda Mugford (School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, England) Yot Teerawattananon (International Health Policy Program, Ministry of Public Health, Nonthaburi, Thailand)
Abstract
Background: There are many effective interventions, via various routes (intravenous [IV], oral [OR], intravitreal injection [IVT] and intraocular implantation [IMP]), for treating cytomegalovirus retinitis (CMVR) that have become available. There are large variations in treating CMVR in clinical practice in Thailand. Objective: To evaluate the incremental cost-effectiveness ratio (ICER) of providing (i) IVT, (ii) IV/OR and (iii) IMP ganciclovir to patients with HIV/AIDS and CMVR versus providing no treatment. Design: A simulation study for which the input parameters were derived from a systematic review of the literature, a hospital-based survey and patient interviews. Setting: The analysis assumed a Thai healthcare system perspective. However, the model was run using both societal and healthcare provider perspectives. Results: Our results suggest that IVT ganciclovir was cost effective and the best option for treating patients with CMVR irrespective of whether patients received antiretroviral treatment (ART). In patients receiving ART, moving from IVT to IV/OR ganciclovir was also likely to be a cost-effective option. Offering IMP ganciclovir was not likely to be cost effective. Providing treatments for patients with bilateral CMVR was more cost effective than providing treatments for those with unilateral CMVR, and offering treatments for patients receiving ART was better value for money than treating patients without ART. Conclusions: Our models suggest that IV/OR ganciclovir should be recommended for the treatment of unilateral and bilateral CMVR for patients receiving ART in the Thai healthcare system. IVT ganciclovir may also have a role in the treatment of CMVR patients not receiving ART.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
file. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Publisher Info
Article provided by Wolters Kluwer Health | Adis in its journal PharmacoEconomics.
Volume (Year): 25 (2007) Issue (Month): 5 () Pages: 413-428 Download reference. The following formats are available: HTML,
plain text,
BibTeX,
RIS (EndNote),
ReDIF
Find related papers by JEL classification: C - Mathematical and Quantitative Methods D - Microeconomics I - Health, Education, and Welfare Z - Other Special Topics I1 - Health, Education, and Welfare - - Health I19 - Health, Education, and Welfare - - Health - - - Other I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets